+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Vertigo Drugs Market 2019-2023 - Product Image

Global Vertigo Drugs Market 2019-2023

  • ID: 4747533
  • Report
  • December 2018
  • Region: Global
  • 122 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE
Vertigo mostly occurs due to inner ear infections or other conditions such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Meniere's disease. These conditions are high-risk factors for vertigo. The prevalence of these risk factors is high globally. Another significant cause for vertigo is vestibular neuritis that is an infection in the inner ears. The infection causes inflammation around the nerves that help the body sense balance. As a result, this infection causes a severe sensation of vertigo that can last for a couple of days and at times coupled with hearing loss. Vestibular neuritis or BPPV may have a low prevalence rate individually. However, when combined, these risk factors of vertigo have a high prevalence rate. As a result, the growth of the global vertigo drugs market would be significant during the forecast period. The analysts have predicted that the vertigo drugs market will register a CAGR of close to 4% by 2023.

Market Overview

Increasing geriatric population

The prevalence of dizziness increases with age. Therefore. rising the geriatric population becomes the driving factor for the growth of the global vertigo drugs market. The aging world population is contributing to the rapid increase in the number of people with vertigo. Therefore, the increasing geriatric population will be driving the growth of the global vertigo drugs market during the forecast period.

Adversely effects of the available therapeutics

The market has the presence of a few approved therapeutics for the treatment of various risk factors of vertigo. These drugs are classified into phenothiazines. antihistamines. benzodiazepines. and others. However. most of these therapeutics cause adverse effects when consumed for a long duration.

For the detailed list of factors that will drive and challenge the growth of the vertigo drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be highly fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antihistamines - Market size and forecast 2018-2023
  • Phenothiazines - Market size and forecast 2018-2023
  • Benzodiazepines - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS
  • Increasing awareness of vertigo and related diseases
  • Strategic alliances for ear diseases
  • Growing e-commerce market
PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global ENT disorders therapeutics market
Exhibit 03: Segments of global ENT disorders therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihistamines - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihistamines - Year-over-year growth 2019-2023 (%)
Exhibit 22: Phenothiazines - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Phenothiazines - Year-over-year growth 2019-2023 (%)
Exhibit 24: Benzodiazepines - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Benzodiazepines - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Increasing prevalence of dizziness with the age
Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Americas
Exhibit 36: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in EMEA
Exhibit 40: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: Geriatric population in APAC
Exhibit 42: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Decision framework
Exhibit 47: Global geriatric population
Exhibit 48: Adverse effects of the drugs
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Awareness initiatives of vertigo
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: F. Hoffmann-La Roche - Vendor overview
Exhibit 57: F. Hoffmann-La Roche - Business segments
Exhibit 58: F. Hoffmann-La Roche - Organizational developments
Exhibit 59: F. Hoffmann-La Roche - Geographic focus
Exhibit 60: F. Hoffmann-La Roche - Segment focus
Exhibit 61: F. Hoffmann-La Roche - Key offerings
Exhibit 62: F. Hoffmann-La Roche - Key customers
Exhibit 63: GlaxoSmithKline - Vendor overview
Exhibit 64: GlaxoSmithKline - Business segments
Exhibit 65: GlaxoSmithKline - Organizational developments
Exhibit 66: GlaxoSmithKline - Geographic focus
Exhibit 67: GlaxoSmithKline - Segment focus
Exhibit 68: GlaxoSmithKline - Key offerings
Exhibit 69: GlaxoSmithKline - Key customers
Exhibit 70: Novartis - Vendor overview
Exhibit 71: Novartis - Business segments
Exhibit 72: Novartis - Organizational developments
Exhibit 73: Novartis - Geographic focus
Exhibit 74: Novartis - Segment focus
Exhibit 75: Novartis - Key offerings
Exhibit 76: Novartis - Key customers
Exhibit 77: Pfizer - Vendor overview
Exhibit 78: Pfizer - Business segments
Exhibit 79: Pfizer - Organizational developments
Exhibit 80: Pfizer - Geographic focus
Exhibit 81: Pfizer - Segment focus
Exhibit 82: Pfizer - Key offerings
Exhibit 83: Pfizer - Key customers
Exhibit 84: Teva Pharmaceutical Industries - Vendor overview
Exhibit 85: Teva Pharmaceutical Industries - Business segments
Exhibit 86: Teva Pharmaceutical Industries - Organizational developments
Exhibit 87: Teva Pharmaceutical Industries - Geographic focus
Exhibit 88: Teva Pharmaceutical Industries - Segment focus
Exhibit 89: Teva Pharmaceutical Industries - Key offerings
Exhibit 90: Teva Pharmaceutical Industries - Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE
Global Vertigo Drugs Market 2019-2023

The author recognizes the following companies as the key players in the global vertigo drugs market: F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness of vertigo and related diseases.”

According to the report, one of the major drivers for this market is the rising healthcare expenditure.

Further, the report states that one of the major factors hindering the growth of this market is the preference of substitutes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll